ArticleFrontiers in immunology2026
Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still's disease: a single-center retrospective study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the effectiveness of tocilizumab (TCZ) combined with short-term high-dose glucocorticoids in rapidly controlling disease activity and reducing glucocorticoid use in patients with adult-onset Still's disease (AOSD). Methods: In this single-center retrospective study, all patients meeting the inclusion criteria were enrolled. Patients receiving short-term high-dose glucocorticoids (5 mg/kg/day for 3 days) with TCZ (400 mg every 4 weeks) were assigned to the TCZ group, while those receiving standard-dose glucocorticoids (1 mg/kg/day) without TCZ formed the non-TCZ group. Efficacy was evaluated based on laboratory data, clinical and Pouchot scores. Glucocorticoids -retention rate was estimated by the Kaplan-Meier method. Results: Fifty patients (11 men, 39 women) were included (19 in the TCZ group and 31 in the non-TCZ group). The TCZ group had a higher incidence of skin rash (100% vs 58.1%, Conclusion: Tocilizumab combined with short-term high-dose glucocorticoids may provide rapid disease control and facilitate glucocorticoid tapering in AOSD. More prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.